Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 756 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Renal Disease Clear all
Completed Phase 2 Interventional Results available

OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO

NCT02819011
View directory record Official record
Conditions
Accidental Falls, Fall Due to Loss of Equilibrium, High Risk of Falls Due to Mobility Limitation, Diabetes, Arthritis, Cancer, Peripheral Arterial Disease, Parkinson's Disease, End Stage Renal Failure on Dialysis
Interventions
MBB AFO, Control
Device · Other
Lead sponsor
Bijan Najafi, PhD
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Peginesatide for Anemia in Chronic Hemodialysis Patients

NCT00228449
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 15, 2026, 9:46 PM EDT
Recruiting Not applicable Interventional

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

NCT06190717
View directory record Official record
Conditions
Diabetes, End Stage Renal Disease
Interventions
EchoMark/EchoSure, Standard of Care
Device · Procedure
Lead sponsor
Sonavex, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

NCT02335099
View directory record Official record
Conditions
End Stage Renal Disease, Vascular Access Patency
Interventions
ticagrelor, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 2Phase 3 Interventional

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

NCT00582777
View directory record Official record
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

NCT01950819
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Interventions
Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Treatment Choice and Outcomes for ESRD: Evidence From the First Year of a Nationwide Randomized Evaluation

NCT05005572
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Payment adjustment for home dialysis and transplant
Other
Lead sponsor
Amy Finkelstein
Other
Eligibility
66 Years and older
Enrollment
18,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Results available

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

NCT01393964
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 15, 2026, 9:46 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

NCT01922999
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease, Sleep Disorder
Interventions
Melatonin
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

NCT00463021
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
8
States / cities
Downey, California • Paramount, California • Hudson, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Improved Induction and Maintenance Immunosuppression in Kidney Transplantation

NCT00556933
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
rabbit anti-thymocyte globulin - single dose, mycophenolate mofetil, rabbit anti-thymocyte globulin - 4 doses, sirolimus, tacrolimus
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 15, 2026, 9:46 PM EDT
Withdrawn Phase 3 Interventional

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

NCT04361552
View directory record Official record
Conditions
Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
Interventions
Best Practice, Tocilizumab
Other · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 4 Interventional

Reference Group Trial for The ONE Study

NCT01656135
View directory record Official record
Conditions
End-stage Renal Failure, Kidney Graft Rejection
Interventions
Blood drawing for immune monitoring and questionnaires
Other
Lead sponsor
University of Regensburg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease

NCT06283589
View directory record Official record
Conditions
Calciphylaxis
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Coral Springs, Florida • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Increasing Kidney Transplant Among Blacks on the Transplant Waiting List

NCT02319447
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
Additional education
Behavioral
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
21 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Not applicable Interventional Results available

Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis

NCT03301740
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UF profiling during HD, Conventional HD
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Carrboro, North Carolina • Siler City, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 15, 2026, 9:46 PM EDT
Terminated No phase listed Observational

Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

NCT01427374
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Dietary Protein Requirements in Hemodialysis Patients

NCT02194114
View directory record Official record
Conditions
Chronic Renal Failure, End-Stage Renal Disease
Interventions
Protein Diet
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Not applicable Interventional Results available

Oral Paricalcitol in Kidney Transplant Recipients

NCT00587158
View directory record Official record
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Omega-3 Fatty Acid Administration in Dialysis Patients

NCT00655525
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
fish oil, placebo
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT

NCT02778516
View directory record Official record
Conditions
ESRD
Interventions
Sodium Restriction
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Results available

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

NCT03934736
View directory record Official record
Conditions
End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions
HEPLISAV-B®
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 15, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

NCT00374803
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Mycophenolic Acid (Myfortic)
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 15, 2026, 9:46 PM EDT
Recruiting Not applicable Interventional

CAPABLE Transplant

NCT06326905
View directory record Official record
Conditions
Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Interventions
CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 15, 2026, 9:46 PM EDT